] . (2019). Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial. PLoS One, 14(9), e0222178. presented at the 2019. doi:10.1371/journal.pone.0222178
. (2015). DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial. PLoS One, 10(5), e0125914. presented at the 2015. doi:10.1371/journal.pone.0125914
. (2011). Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.. Vaccine, 29(34), 5666-74. presented at the 2011 Aug 05. doi:10.1016/j.vaccine.2011.06.010
. (2009). Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine, 27(37), 5091-5. presented at the 2009 Aug 13. doi:10.1016/j.vaccine.2009.06.057
. (2008). Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis, 197(5), 667-75. presented at the 2008 Mar 01. doi:10.1086/527489
. (2005). Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. J Infect Dis, 192(12), 2092-8. presented at the 2005 Dec 15. doi:10.1086/498172
. (2002). Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine, 20(7-8), 1099-105. presented at the 2002 Jan 15. doi:10.1016/s0264-410x(01)00440-6